Remicade Injection (Infliximab) | Used to Treat Rheumatoid Arthritis and Crohn’s Disease
Remicade Injection (Infliximab) is a biologic therapy used to treat various autoimmune and inflammatory conditions. As a TNF-alpha inhibitor, it helps reduce inflammation and alleviate symptoms associated with diseases like rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
Product Overview
Remicade Injection is a pioneering biological medication containing Infliximab, a chimeric monoclonal antibody designed to manage chronic and severe autoimmune diseases. As a premier TNF-alpha blocker, it targets the biological roots of systemic inflammation, offering a life-changing solution for patients who have not responded to conventional therapies. This intravenous biologic therapy is engineered to halt tissue destruction and induce long-term remission in conditions affecting the joints, skin, and digestive tract.
Product Composition
- Infliximab: The active biological substance (100mg per vial), a chimeric human-murine IgG1κ monoclonal antibody that neutralizes specific inflammatory proteins.
- Sucrose: Acts as a stabilizing agent to protect the protein structure of the antibody during the lyophilization (freeze-drying) process.
- Polysorbate 80: A surfactant included to prevent the aggregation of the active drug molecules and ensure a clear solution upon reconstitution.
- Sodium Phosphate (Monobasic & Dibasic): Essential buffering agents used to maintain a stable physiological pH for safe intravenous infusion.
Product Specification
| Feature | Details |
| Therapeutic Class | Tumor Necrosis Factor (TNF) Blocker |
| Pharmaceutical Form | Lyophilized Powder for Solution for Infusion |
| Molecular Weight | Approximately 149,100 Daltons |
| Bioavailability | 100% via Intravenous Route |
| Half-Life | 7.7 to 9.5 Days |
Mechanism of Action
- Remicade works by binding with high affinity to both the soluble and transmembrane forms of tumor necrosis factor-alpha (TNF-alpha).
- By neutralizing TNF-alpha, it prevents this pro-inflammatory cytokine from binding to its receptors, effectively shutting down the signaling pathways that drive chronic inflammation.
- The medication facilitates complement-mediated lysis and apoptosis of activated T-lymphocytes and macrophages that overproduce inflammatory signals.
- It reduces the infiltration of inflammatory cells into affected tissues and lowers the expression of adhesion molecules, preventing further tissue damage.
- Treatment results in a rapid decrease in systemic markers of inflammation, such as C-reactive protein (CRP) and Interleukin-6 (IL-6).
Key Benefits
- Highly effective at inducing and maintaining clinical remission in moderate to severe Crohn's disease and ulcerative colitis.
- Proven to significantly reduce joint pain and swelling in patients with rheumatoid arthritis, especially when used with methotrexate.
- Slows the progression of structural joint damage, helping patients maintain physical function and mobility over time.
- Provides rapid clearing of plaque psoriasis lesions and improves skin-related quality of life for patients with chronic dermatological conditions.
- A gold-standard treatment for fistulizing Crohn's disease, helping to close and maintain the closure of abnormal passageways.
- Offers a convenient maintenance schedule, typically administered every 6 to 8 weeks after the initial induction phase.
Precautions
| General Precaution | Details |
|---|---|
| Use only under supervision | Remicade Injection must be given by a healthcare professional |
| Hospital administration | Usually administered as an infusion in a clinical setting |
| Do not self-administer | Improper use can cause serious complications |
| Screening required | Patients should be tested for infections before starting |
| Regular monitoring | Ongoing medical checks are required during therapy |
Medical Supervision
- Always use under specialist care
- Inform doctor about any past or current infections
- Share full medical history including TB exposure
Infection Risk Precautions
- May increase risk of serious infections
- Avoid contact with people having active infections
- Report fever, cough or unusual symptoms immediately
Health Condition Precautions
- Caution in patients with tuberculosis or hepatitis
- Use carefully in heart failure patients
- Monitor closely in patients with weakened immunity
During Treatment Care
- Attend all scheduled infusion appointments
- Regular blood tests may be required
- Do not miss follow-up visits
Pregnancy and Breastfeeding
- Use only if clearly prescribed by a doctor
- Risk vs benefit must be carefully evaluated
Safety Advice
- Avoid live vaccines during treatment unless approved
- Inform doctor about all medications being used
- Store and handle only in clinical settings as advised
Usage
The administration of Infliximab follows a specific induction and maintenance regimen to achieve and sustain therapeutic drug levels in the bloodstream.
Administration
Intravenous Infusion Only: Remicade must be administered by a healthcare professional via a slow IV infusion over a period of no less than 2 hours.
Reconstitution Protocol: The lyophilized powder must be carefully reconstituted with Sterile Water for Injection and then further diluted with 0.9% Sodium Chloride.
In-Line Filter: The infusion set must include a sterile, non-pyrogenic, low protein-binding filter (pore size 1.2 micrometers or less) to ensure purity.
Observation Period: Patients must be monitored during and for at least 1 to 2 hours after the infusion for signs of infusion-related reactions or hypersensitivity.
Pre-medication: In some cases, antihistamines or acetaminophen are administered prior to the dose to prevent acute infusion reactions.
Uses
Induction and maintenance of clinical remission in adult and pediatric patients with moderate to severe active Crohn’s Disease.
Treatment of fistulizing Crohn’s Disease, specifically for reducing the number of draining enterocutaneous and rectovaginal fistulas.
Management of moderate to severe Ulcerative Colitis in patients who have had an inadequate response to conventional therapy.
Inhibition of the progression of structural damage and improvement of physical function in patients with Rheumatoid Arthritis.
Reduction of signs and symptoms of Ankylosing Spondylitis, a chronic inflammatory arthritis affecting the spine.
Long-term treatment of Chronic Plaque Psoriasis in adults who are candidates for systemic therapy or phototherapy.
Control of joint inflammation and skin manifestations in patients with Active Psoriatic Arthritis.
Side Effects
Common Side Effects
- Headache
- Nausea
- Upper respiratory infections
- Abdominal pain
- Injection or infusion site reactions
Less Common Side Effects
- Rash or itching
- Fever
- Fatigue
- Sinus infections
- Dizziness
Serious Side Effects
| Serious Side Effect | Details |
|---|---|
| Severe infections | Tuberculosis or other serious infections may occur |
| Allergic reactions | Swelling, rash, or breathing difficulty |
| Heart failure worsening | May aggravate existing heart conditions |
| Liver problems | Yellowing of skin or abnormal liver tests |
| Blood disorders | Unusual bruising or low blood counts |
When to Seek Medical Help
- If you develop persistent fever or signs of infection
- If severe allergic reactions such as swelling or breathing issues occur
- If unusual fatigue, bruising, or bleeding appears
- If chest pain or breathing difficulty develops
FAQs
Q: What is Remicade Injection used for?
A: Remicade Injection is used to treat chronic inflammatory conditions including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and moderate to severe plaque psoriasis.
Q: How does Remicade Injection work?
A: Infliximab works by binding to and neutralizing tumor necrosis factor-alpha (TNF-α), a protein that drives chronic inflammation, thereby reducing inflammation and preventing further tissue and joint damage.
Q: How is Remicade Injection administered?
A: It is administered as a slow intravenous infusion over at least 2 hours by a qualified healthcare professional in a hospital or infusion center, with close monitoring during and after the infusion.
Q: What is the recommended dose of Remicade Injection?
A: The usual starting dose is 3–5 mg/kg body weight, followed by additional doses at 2 and 6 weeks, then every 8 weeks thereafter. The dose may vary depending on the condition being treated.
Q: How long does Remicade treatment last?
A: Remicade is typically used as a long-term maintenance therapy. The duration of treatment depends on the patient's response and the condition being managed, as determined by the doctor.
Q: What are the common side effects of Remicade Injection?
A: Common side effects include infusion reactions such as fever, chills, and headache, as well as upper respiratory tract infections, nausea, fatigue, and abdominal pain.
Q: Can Remicade Injection cause serious infections?
A: Yes, as Infliximab suppresses the immune system, it increases the risk of serious infections including tuberculosis, bacterial sepsis, and opportunistic infections. Screening for tuberculosis is mandatory before starting treatment.
Q: Is Remicade Injection safe during pregnancy or breastfeeding?
A: Use during pregnancy should be carefully evaluated by the doctor. Infliximab can cross the placenta, particularly in the third trimester. Breastfeeding is generally not recommended during treatment.
Q: Can Remicade Injection be used in children?
A: Yes, Remicade is approved for use in children with Crohn's disease and ulcerative colitis aged 6 years and above, under strict medical supervision with appropriate dose adjustment.
Q: Can Remicade Injection increase the risk of cancer?
A: Long-term use of TNF-α inhibitors has been associated with a slightly increased risk of certain cancers, including lymphoma. Discuss the risks and benefits thoroughly with your doctor before starting treatment.
Q: What drugs interact with Remicade Injection?
A: Remicade may interact with other immunosuppressants such as methotrexate, azathioprine, and live vaccines. Inform your doctor about all current medications before starting treatment.
Q: What precautions should be followed during Remicade therapy?
A: Screen for tuberculosis and hepatitis B before starting treatment, avoid live vaccines during therapy, report any signs of infection immediately, and attend all scheduled infusion appointments for regular monitoring of treatment response and safety.
Interactions
| Interaction Type | Details |
|---|---|
| Other biologics | Increased risk of serious infections |
| Live vaccines | May cause infection; should be avoided |
| Immunosuppressants | Higher risk of infections and immune suppression |
| Methotrexate | Commonly used together but requires monitoring |
| Corticosteroids | May increase infection risk when combined |
Medicine Interactions
- Inform your doctor about all medicines before starting Remicade
- Avoid combining with other TNF blockers unless prescribed
- Use caution with drugs that suppress the immune system
Vaccine Interactions
- Do not receive live vaccines during treatment
- Vaccination schedule should be reviewed before starting therapy
- Always consult your doctor before any immunization
Disease Related Interactions
- Increased infection risk in patients with TB or hepatitis
- Caution in patients with heart failure
- May worsen existing infections if not controlled
Important Safety Advice
- Report fever, cough, or signs of infection immediately
- Regular monitoring is required during therapy
- Follow infusion schedule strictly as prescribed
| Manufacturer | : | Janssen Pharmaceuticals |
| Trade Name | : | Remicade |
| Generic Search | : | Infliximab |
| Strength | : | 100MG |
Latest Products
